PacBio announced a collaboration with the University of Tokyo, Graduate School of Medicine to study the use of long-read sequencing and novel bioinformatics methods in the hopes of better understanding the genetic causes of certain rare diseases in individuals and cohorts within the Japanese population.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PACB:
- PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022
- Pacific Biosciences sees Q4 revenue $27.3M, consensus $27.88M
- Pacific Biosciences initiated with an Outperform at Scotiabank
- Pac Bio call volume above normal and directionally bullish
- Pacific Biosciences to host investor day
